oral glp-1 medications approved BREAKING: The FDA has the first pill for obesity, marking a major milestone in the weight-loss drug market and a potential inflection point for treatment access. The daily pill Oral GLP-1-Based Therapeutics in the

Potent body weight loss and efficacy in a NASH animal model by a novel long-acting GLP-1/Glucagon/GIP triple-agonist (HM15211)

Theyre approved for use alongside lifestyle changes, including increased physical activity and decreased caloric intake (usually eating 500 fewer calories per day)

Providers are increasingly seeing side effects such as: Nausea, vomiting, and delayed gastric emptying Fatigue and muscle loss during rapid weight loss Micronutrient depletion from reduced food intake Emotional dysregulation related to appetite and blood sugar swings Plateaus or weight regain after discontinuation Some patients also feel disconnected from their hunger cues or experience anxiety about long-term dependency on injections

Blanco, et al (2014)

Nearly 40% of adults age 60 and older qualified as obese in 2023, according to the Centers for Disease Control and Prevention